New drug combo for weight loss enters early human testing
NCT ID NCT06916065
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called eloralintide, alone or combined with tirzepatide, in 188 adults with overweight or obesity. The main goals are to check safety, side effects, and how the drugs move through the body. Participants receive weekly injections under the skin for up to 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Eloralintide and tirzepatide
What this could lead to
If successful, this could point toward a new weight-loss treatment option for people with overweight or obesity.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not on weight loss. It is small and may not lead to an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States